Business Context and Reporting Period
This Form 8-K is a current report filed by EyeGate Pharmaceuticals, Inc. (not Kiora Pharmaceuticals as indicated in metadata) on January 3, 2020. The registrant is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol EYEG. The report addresses a corporate governance event rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a personnel change and does not contain financial statements or operational metrics.
Material Changes
The material change reported is the departure of a director:
- Event: Peter Greenleaf resigned from the Board of Directors.
- Date: January 3, 2020.
- Reason: Personal reasons.
- Disagreement Status: The resignation was not the result of any disagreements with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure regarding the director's resignation.
Investor Verification Checklist
- Verify the correct registrant name is EyeGate Pharmaceuticals, Inc. (EYEG), not Kiora Pharmaceuticals.
- Confirm the impact of Peter Greenleaf's departure on the Board's composition and committee assignments.
- Review subsequent filings for any new director appointments to fill the vacancy.